2020年12月至2021年8月德国COVID-19疫苗接种后罕见吉兰-巴雷综合征病例
分析德国2020年12月27日至2021年8月31日安全监测数据,按Brighton Collaboration标准验证吉兰-巴雷综合征(GBS)病例。对符合BC 1至4级的病例进行观察vs预期分析,Vaxzevria和COVID-19 Vaccine Janssen接种后GBS病例数分别为预期的约3倍和4倍。
要点
- Vaxzevria接种后3-42天GBS标准化发病比估计值为3.10(95%CI:2.44-3.88)。
- COVID-19 Vaccine Janssen接种后GBS标准化发病比估计值为4.16(95%CI:2.64-6.24)。
- Vaxzevria和COVID-19 Vaccine Janssen接种后GBS病例中双侧面瘫报告率分别为19.7%和26.1%。
核心结论
- Vaxzevria和COVID-19 Vaccine Janssen接种后报告的GBS病例数分别约为预期的3倍和4倍,因此GBS可能是基于载体疫苗的不良事件。
- 基于载体COVID-19疫苗后GBS病例中双侧面瘫较mRNA COVID-19疫苗后更常见。
研究设计与样本
- 分析德国国家主管机构2020年12月27日至2021年8月31日报告的安全监测数据。
- GBS病例按Brighton Collaboration(BC)标准验证。
- 对符合BC 1至4级的病例进行观察vs预期(OvE)分析,涵盖四种欧洲药品管理局批准的COVID-19疫苗和流感疫苗。
主要发现
- COVID-19疫苗接种后共报告214例GBS病例,其中156例符合进一步分析条件。
- 接种后3-42天标准化发病比估计值:Comirnaty为0.34(95%CI:0.25-0.44),Spikevax为0.38(95%CI:0.15-0.79),Vaxzevria为3.10(95%CI:2.44-3.88),COVID-19 Vaccine Janssen为4.16(95%CI:2.64-6.24),流感疫苗为0.60(95%CI:0.35-0.94)。
- 156例GBS病例中,Vaxzevria和COVID-19 Vaccine Janssen接种后双侧面瘫报告率分别为19.7%和26.1%,Comirnaty暴露病例中仅为6%。
关键数值与推荐
- GBS病例按Brighton Collaboration(BC)标准验证,分析纳入BC 1至4级病例。
- 标准化发病比估计值基于接种后3-42天。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BackgroundGuillain-Barré syndrome (GBS) has been associated with vaccination against COVID-19.AimWe aimed to compare clinical characteristics and analyse excess GBS cases following administration of different COVID-19 and influenza vaccines in Germany versus the expected numbers estimated from pre-pandemic background incidence rates.MethodsWe analysed safety surveillance data reported to the German national competent authority between 27 December 2020 and 31 August 2021. GBS cases were validated according to Brighton Collaboration (BC) criteria. We conducted observed vs expected (OvE) analyses on cases fulfilling BC criteria levels 1 to 4 for all four European Medicines Agency-approved COVID-19 vaccines and for influenza vaccines.ResultsA total of 214 GBS cases after COVID-19 vaccination had been reported, of whom 156 were eligible for further analysis. Standardised morbidity ratio estimates 3-42 days after vaccination were 0.34 (95% confidence interval (CI): 0.25-0.44) for Comirnaty, 0.38 (95% CI: 0.15-0.79) for Spikevax, 3.10 (95% CI: 2.44-3.88) for Vaxzevria, 4.16 (95% CI: 2.64-6.24) for COVID-19 Vaccine Janssen and 0.60 (95% CI: 0.35-0.94) for influenza vaccines. Bilateral facial paresis was reported in 19.7% and 26.1% of the 156 GBS cases following vaccination with Vaxzevria and COVID-19 Vaccine Janssen, respectively, and only in 6% of cases exposed to Comirnaty.ConclusionThree and four times more GBS cases than expected were reported after vaccination with Vaxzevria and COVID-19 Vaccine Janssen, respectively, therefore GBS might be an adverse event of vector-based vaccines. Bifacial paresis was more common in cases with GBS following vaccination with vector-based than mRNA COVID-19 vaccines.
引用
- Lehmann HC, Oberle D, Keller-Stanislawski B, et al. Rare cases of Guillain-Barré syndrome after COVID-19 vaccination, Germany, December 2020 to August 2021. Euro Surveill. 2023. PMID: 37318764. doi:10.2807/1560-7917.ES.2023.28.24.2200744
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。